摘要
探讨胺碘酮对冠心病无症状心肌缺血 (SMI)伴室性早搏 (简称室早 )的治疗效果。将 6 1例冠心病伴室早患者随机分为 2组 ,其中 31例口服胺碘酮片作为治疗组 ,30例应用硝酸异山梨酯片作为对照组。结果 :治疗组用药后SMI的发作次数显著降低 (78.7± 7.6vs 2 0 5± 11.0次 ,P <0 .0 1)及其持续总时间显著缩短 (90 .2± 11.4vs 5 0 0 .5± 39.2min ,P <0 .0 1) ,同时室早亦显著减少 (10 5± 2 7vs 90 9± 6 2次 ,P <0 .0 1)。对照组SMI发作次数亦明显降低(135 .1± 10 .8vs 2 0 4.8± 12 .5次 ,P <0 .0 1)及持续时间缩短 (2 11.7± 30 .5vs 499± 40 .3,P <0 .0 1) ,室早减少 (76 9±6 1vs 910± 6 3次 ,P <0 .0 5 )。治疗组与对照组之间比较有显著性差异 (P均 <0 .0 5 )。未见胺碘酮严重副作用。结论 :胺碘酮对冠心病伴室早有显著疗效 ,优于硝酸异山梨酯片。
To explore the efficiency of amiodarone on treating silent myocardial ischemia(SMI) and ventricular premature beats(VPBs) with coronary heart disease.Sixty one cases of SMI with VPBs in coronary heart disease were randomly into two groups:treatment group (31 cases) was treated with amiodrarone;control group(30 cases) was treated with sorbitrate.Results:In treatment group,the occurrence of SMI was significicantly reduced(78.7±7.6 vs 205±11.0 times, P<0.01 )and the total continuative time was shorted significantly(90.2±11.4 vs 500.5±39.2 min, P<0.01 )as well as VPBs was also reduced significantly(105±27 vs 902±62 bpm, P<0.01 ).While in control group,the occurrence of SMI was reduced significantly(135.1±10.8 vs 204.8±12.5 times, P<0.01 )and the total continuative time was shortened significantly(211.7±30.5 vs 499±40.3 min, P<0.01 ),the VPBs was reduced(796±61 vs 910±63 bpm, P<0.05 ).Moreover,there was obvious difference between two groups(all P<0.05 ).No severe adverse effect was found.Conclusion:there was obvious therapeutic efficacy of amiodarone on SMI with VPBs in coronary heart disease,it is better than sorbitrate.
出处
《中国心脏起搏与心电生理杂志》
2001年第5期315-316,共2页
Chinese Journal of Cardiac Pacing and Electrophysiology